The new treatment is developed by the accelerated evolution biotechnology pharmaceutical laboratory led by the CEO, Dr. Ilan Morad, according to the report.
"We believe we will offer complete cancer treatment during the year"he said Dan Aridor, Chairman of the Board. "Our cancer treatment will be effective from day one, it will last for a few weeks, with minimal side effects or not much lower than most other treatments".
Treatment, called "MuTaTo", will use a combination of anti-cancer peptide and toxin that will specifically kill cancer cells.
The treatment will eventually be personalized and patients will be given a special drug cocktail according to their type of cancer, Morad said.
Despite the importance of the statement, some voices question the operation of the new treatment, for example, considering that it has only been tested in mice.
In this regard, Deputy Director of Medical of the National Office of the American Cancer Society Len Lichtenfeldsaid the agency's blog "It goes without saying that we all share the hope that they are right".
"Unfortunately, we must be aware that it is far from effective treatment for people with cancer, not to mention treatment"., he said.
Finally, the expert noted that Israeli researchers have not publicly disclosed the data collected to justify his statement, nor do they disclose evidence that treatment has been successful in mice, indicating that so far everyone has done an interview with the local media according to published site publimetro.cl.